Q3 EPS Estimate for Mirum Pharmaceuticals Cut by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities researchers at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce now expects that the company will post earnings of $0.35 per share for the quarter, down from their previous forecast of $0.46. HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at $0.61 EPS.

Several other equities analysts also recently weighed in on the company. Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday. Evercore ISI lifted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Citigroup upped their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Trading Up 3.9 %

NASDAQ:MIRM opened at $43.92 on Thursday. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The firm has a fifty day simple moving average of $39.96 and a 200-day simple moving average of $35.79. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $45.81. The company has a market capitalization of $2.10 billion, a P/E ratio of -21.74 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. During the same period last year, the firm posted ($0.57) EPS.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently bought and sold shares of MIRM. Janus Henderson Group PLC lifted its position in shares of Mirum Pharmaceuticals by 34.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock worth $69,470,000 after buying an additional 704,659 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Mirum Pharmaceuticals by 37.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after acquiring an additional 432,824 shares in the last quarter. Clearbridge Investments LLC lifted its position in Mirum Pharmaceuticals by 165.5% in the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Mirum Pharmaceuticals by 8.1% in the second quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock valued at $23,179,000 after acquiring an additional 50,667 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth about $17,384,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.